Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

9.710 -0.110 (-1.12%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,573,588
Open 9.820
Bid (Size) 9.700 (10)
Ask (Size) 9.870 (10)
Prev. Close 9.820
Today's Range 9.610 - 9.870
52wk Range 7.085 - 11.45
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat

Performance

YTD
+1.89%
+1.89%
1 Month
+10.84%
+10.84%
3 Month
-1.32%
-1.32%
6 Month
+34.30%
+34.30%
1 Year
+11.61%
+11.61%

More News

Read More
Israel And Hamas Agree To Extend Truce By 2 Days; Elon Musk Wishes For World Peace After Visiting Israel
Via Benzinga
What To Know About UBS's Upgrade of Teva Pharmaceutical Indus
Via Benzinga
Ituran Location and Control Posts Q3 Results, Joins Crown Castle, Shopify And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
CrowdStrike To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
3 Resilient Stocks with Massive Potential to Boost Your Wealth
Via InvestorPlace
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
2 overlooked stocks that crushed earnings but traded lower
Via MarketBeat
Exposures Product Safety
Resilient Large Cap Israeli- Domiciled U.S. Exchange-Listed Stocks Up 16.5% Last Week
Via Talk Markets
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tuesday Talk: What's Going On?
Via Talk Markets
Topics Stocks
Exposures US Equities
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
From Royalty Pharma plc
Via GlobeNewswire
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
Israel-Hamas War News: Top 15 Israeli-Based US-Traded Stocks Continue To Slide
Via Talk Markets
Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Teva Pharmaceutical Lifts Revenue Forecast - Huntington's And Migraine Drugs Help Q3 Performance
Via Benzinga
Teva Closes In On A Buy Point On Third-Quarter Beat, Business Separation
Via Investor's Business Daily
US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
From Teva Pharmaceutical Industries Limited
Via Business Wire
Earnings Scheduled For November 8, 2023
Via Benzinga
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 Outlook
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.